The study of de novo point mutations (new germline mutations arising from the gametes of the parents) remained largely static until the arrival of next-generation sequencing technologies, which made both whole-exome sequencing (WES) and whole-genome sequencing (WGS) feasible in practical terms. Single nucleotide polymorphism genotyping arrays have been used to identify de novo copy-number variants in a number of common neurodevelopmental conditions such as schizophrenia and autism. By contrast, as point mutations and microlesions occurring de novo are refractory to analysis by these microarraybased methods, little was known about either their frequency or impact upon neurodevelopmental disease, until the advent of WES. De novo point mutations have recently been implicated in schizophrenia, autism and mental retardation through the WES of case-parent trios. Taken together, these findings strengthen the hypothesis that the occurrence of de novo mutations could account for the high prevalence of such diseases that are associated with a marked reduction in fecundity. De novo point mutations are also known to be responsible for many sporadic cases of rare dominant Mendelian disorders such as Kabuki syndrome, Schinzel--Giedion syndrome and Bohring--Opitz syndrome. These disorders share a common feature in that they are all characterized by intellectual disability. In summary, recent WES studies of neurodevelopmental and neuropsychiatric disease have provided new insights into the role of de novo mutations in these disorders. Our knowledge of de novo mutations is likely to be further accelerated by WGS. However, the collection of case-parent trios will be a prerequisite for such studies. This review aims to discuss recent developments in the study of de novo mutations made possible by technological advances in DNA sequencing.
INTRODUCTION
Germline mutations arise anew in each generation during meiosis. Such spontaneously occurring lesions are termed de novo mutations that is, heritable mutations that neither parent possessed or transmitted. De novo mutations refer to mutations that arose in the gametes of the parents. They are not easily distinguished from the new/de novo mutations that arise somatically in the offspring, as both types of mutations are undetectable in the parents. To avoid confusion, de novo is used here specifically to denote mutations that have arisen from the gametes of the parents during meiosis. The presence of variants not found in a given individual's parents may also be due to postzygotic mutations that have attained a high level of somatic mosaicism either because they occurred at an early stage of embryonic development or because they conferred a survival or proliferation advantage upon the cells harboring them. As current methodology cannot distinguish between the two instances, they will be discussed together under the de novo term.
As with inherited mutations, de novo mutations range in size from single nucleotide variants (SNVs)/point mutations and other microlesions to much larger copy-number variants (CNVs) and structural rearrangements. Although they arise spontaneously in each generation, their incidence in the entire human genome is difficult to estimate owing to the lack of appropriate tools. Further, regional differences in the mutation rate across the genome (for example, coding versus non-coding regions, or evolutionarily conserved versus non-conserved regions) and between families and populations have been largely refractory to analysis. Hence, the relative contributions of de novo mutations from the paternal and maternal sets of chromosomes in offspring have until recently also remained largely unclear. 1 Finally, the molecular features or factors that influence the de novo mutation rate in the human genome are subject to speculation but might include chromosomal location, length of coding sequence, number and length of introns, nucleotide composition (for example, GC level), sequence repetitivity both within and flanking the gene, and the efficiency of DNA repair mechanisms. 2 Our inability to identify de novo mutations both genome wide in a given individual or within specific populations has precluded the estimation of the proportions of mutations, respectively, predicted to be neutral (genetic drift), advantageous (positive selection) and deleterious (purifying selection) using available bioinformatic tools such as SIFT, PolyPhen and ANNOVAR. 3--5 However, these prediction tools have comparatively high error rates. For example, the sensitivity of SIFT and PolyPhen was reasonably high that is, B70%, but their specificity was low that is, o20%. 6 This suggests that although SIFT and PolyPhen may be useful in prioritizing variants that are likely to be deleterious resulting in a loss-of-protein function, their low specificity also requires that their predictions should be interpreted with a degree of caution. The specificity of the functional prediction might be increased by applying more stringent criteria, for example, by seeking consistency in prediction of deleterious mutations by several different algorithms and/or by incorporating evolutionary conservation data. However, further evidence beyond the in silico predictions is invariably needed to support or exclude the pathological significance of newly detected missense variants.
In addition to the need for case-parent trios, studying de novo mutations on a genome-wide scale requires a whole-genome screening tool. Clearly, comparison with the parental genomes is necessary to distinguish from inherited variants. Although the conventional gene-centric approach of limited Sanger sequencing is capable of identifying de novo point mutations, this method cannot realistically be scaled up to the entire genome, exome or even to thousands of genes. The targeted sequencing of candidate genes has been successful in identifying numerous de novo point mutations underlying a variety of neurodevelopmental conditions. 7, 8 However, it is a hypothesis-driven approach. The selection of candidate genes is highly dependent upon an a priori hypothesis, which is in turn constrained by our still limited knowledge of the biological pathways that characterize the diseases in question. Most of the candidate genes were selected on the basis of their biological plausibility; as a result, this will have rendered unlikely the discovery of new or unexpected genes/ pathways affected by de novo mutations underlying these diseases. Although the availability of multiple oligonucleotidecomparative genomic hybridization and single nucleotide polymorphism (SNP) genotyping arrays has provided new opportunities to study de novo events at the whole-genome level, the application of this methodology is limited to the analysis of CNVs. 9, 10 By contrast, the arrival of next-generation sequencing (NGS) technologies has revolutionized the detection and analysis of microlesions occurring de novo, allowing first estimations of the mutation rate as well as a glimpse of the spatial distribution of de novo mutations in the human genome 11 and their association with heritable disease. 12 Thus, the whole-genome sequencing (WGS) approach (by mapping or aligning sequence reads against a reference genome) should lead to the identification of different types of de novo mutation within case-parent trios. However, the comprehensive identification of de novo mutations would necessarily require a de novo genome assembly approach 13 where the sequence reads are assembled into contigs that are then compared between genomes to identify variants. WGS studies performed to date have employed the mapping approach, both because of the short sequence reads generated but also because of the current lack of powerful de novo assembly tools. 14--16 Owing to technical limitations, the contribution of de novo mutations to human genetic disease (both Mendelian disorders and complex diseases) has remained largely unexplored. De novo mutations could have severe biological or phenotypic consequences when they affect functionally important nucleotides in the genome (for example, nonsense mutations leading to truncated proteins) or when they occur in evolutionarily conserved regions. However, only a relatively small proportion of the de novo mutations occurring at each meiosis will affect functionally important nucleotides. Although de novo CNVs have been shown, using whole-genome SNP genotyping arrays, to be associated with various common neurodevelopmental diseases, 9,10 it was not until very recently that de novo point mutations were also implicated in the etiology of schizophrenia, autism and mental retardation through the whole-exome sequencing (WES) of affected trios. 12,17--19 In a similar vein, de novo point mutations have also been found to be responsible for sporadic cases of various rare dominant Mendelian disorders such as Kabuki syndrome, Schinzel--Giedion syndrome and Bohring--Opitz syndrome. 20--22 These Mendelian disorders are also characterized by multiple neurodevelopmental defects; thus, for example, Bohring--Opitz syndrome is a clinically recognizable syndrome characterized by severe intellectual disability, distinctive facial features and multiple congenital malformations. 22 In this review, we appraise the recent paradigm shift in the study of de novo mutations as a consequence of the availability of new sequence data emerging through technological advances in sequence capture methods and NGS technologies, which have potentiated both WES and WGS. We also review the identification of de novo point mutations in various neurodevelopmental and neuropsychiatric conditions by means of WES. Finally, we discuss future directions in the study of de novo mutations.
THE TECHNOLOGICAL ADVANCES THAT LED TO THE EMER-GENCE OF A NEW PARADIGM IN THE STUDY OF DE NOVO MUTATIONS
Owing to technical limitations, it used not to be possible to study the occurrence and pathological relevance of de novo mutations in the context of the entire human genome. This all changed with technological advances in oligonucleotide-comparative genomic hybridization and SNP genotyping arrays that enabled highresolution CNV analysis (compared with lower resolution methods such as traditional cytogenetic analysis and bacterial artificial chromosome clone microarrays), thereby providing us with the first opportunity to perform relatively unbiased genome-wide surveys of these mutations in a variety of different disease states. 23--25 High-density SNP genotyping arrays have been the mainstay of the genome-wide association studies that have sought to identify associations of SNPs with various complex diseases. 26 It also became apparent that these arrays would allow CNVs to be investigated on the basis of their signal intensity. Two types of signal intensity data are generated that is, (a) the total signal intensity (or log ratio) and (b) the allelic intensity ratio or B allele frequency. The combination of log ratio and B allele frequency can be used to determine several different copy-number states such as homozygous and heterozygous deletions, and one-copy or two-copy duplications, as implemented in multiple CNV-calling algorithms. 27, 28 Figure 1 illustrates the difference in log ratio and B allele frequency patterns between a deletion and a duplication.
Copy-number variation is one of the most intriguing types of human genetic polymorphism discovered over the past few years; it generally refers to deletions or duplications that are typically larger than 1 kb in size. 29--31 Many studies have now been performed to examine the associations of CNVs with complex diseases, using SNP genotyping arrays. These studies have yielded somewhat mixed results. The study performed by the Wellcome Trust Case Control Consortium, which investigated the association between B3400 common CNVs and 8 complex diseases (that is, bipolar disorder, breast cancer, coronary artery disease, Crohn's disease, hypertension, rheumatoid arthritis, type 1 diabetes and type 2 diabetes) in 19 000 samples, served as a proof of principle and did not itself yield any novel discoveries. 32 By contrast, numerous CNVs have been identified for various neurodevelopmental and neuropsychiatric disorders such as autism/autism spectrum disorders (ASD), 9, 33 schizophrenia, 10,34--36 mental retardation 37 as well as bipolar disorder. 38 More importantly, de novo CNVs have also been discovered in the context of several neurodevelopmental diseases (discussed below). The paucity of CNV associations with non-neurodevelopmental diseases is currently unclear. However, it should be noted that common CNVs were the main focus of the Wellcome Trust Case Control Consortium study. In sharp contradistinction, it has been de novo and rare CNVs that have been found to be associated with various neurodevelopmental disorders. Further, rare CNVs have not been widely tested for their associations with complex non-neurodevelopmental diseases; this could be because of the concepts encapsulated in the common disease-common variant model. The notion that neurodevelopmental diseases could be subject to stronger purifying selection pressure is somewhat speculative; hence, the underlying causal mutations are individually rare or could have arisen de novo, but collectively contribute to the commonness of the diseases.
Although some success has been achieved in the study of de novo CNVs by means of SNP genotyping arrays, de novo point mutations and microlesions have until recently remained refractory to analysis. The advent of NGS technologies has provided new opportunities to explore this latter type of mutation. The output of these NGS platforms is a very large number of sequence reads (up to hundreds of millions). The read lengths vary from B100 bp (Illumina Genome Analyzer (Illumina, San Diego, CA, USA)/HiSeq or ABI SOLiD, Life Technologies, Grand Island, NY, USA) to several hundreds of base pairs (Roche 454 GS FLX, Roche Diagnostics, Mannheim, Germany). 39, 40 The designs of the sequencing experiments are such that each nucleotide (either in the exome or whole genome) is represented in a large number of different reads, typically at least 30-fold on average (depth of sequencing). Naturally, the coverage of specific sequences varies around this average, with the minimum coverage required to call a variant depending upon homozygosity versus heterozygosity and on the error rate of the method employed. Although the raw base-calling error rate is much higher for all NGS technologies than for Sanger sequencing, this may be remedied by increasing the depth of sequencing to improve the consensus accuracy. However, a minimum of eight-fold coverage is deemed sufficient for accurate detection of inherited SNVs. In addition, SNV detection is very sensitive to the mapping quality, as false positives could result from misalignment of the reads to the reference genome. Misalignment of reads is attributed to the fact that the human genome has a significant portion of homologous regions, in particular paralogous loci. However, these alignment artifacts can be reduced in number by using paired-end sequencing (together with a longer sequence read length, for example, 100 bp) as there is a very low likelihood with this approach that misalignment occurs for both reads. In addition, the misalignment can also be alleviated by scoring the SNVs according to the uniqueness of their genomic locations. The UCSC genome browser provides a tool that allows all genomic regions to be assigned to their corresponding homologous regions if they exist (UCSC Self Chain Track).
Thus, the massive throughput of NGS technologies has enabled WES and WGS to become technically feasible. NGS is a very powerful tool to study SNVs, as it has a fairly high sensitivity and specificity rate (490%) for detecting SNVs. Although the reported specificity rate for small indels and structural rearrangements is much lower, B30--70%, sensitivity is difficult to estimate as the true number of variants is unknown. 20,41--43 Thus, both WES and WGS in their current forms are good enough to study de novo point mutations, but probably not as yet good enough for other types of lesions. These NGS technologies, when coupled with sequence-enrichment methods and applied to case-parent trio samples, have revolutionized the way in which we identify the de novo point mutations, and to a lesser extent other mutation types through WES. 1,12,17--19 Indeed, these WES studies have used the commercial whole-exome enrichment kits coupled with NGS technologies (Table 1 ). The lower cost of WES, and the fact that it is less analytically challenging compared with the WGS approach, are probably the major reasons for the wide acceptance of WES.
Log ratio

B allele frequency
One copy duplication
Normal diploid copy
One copy deletion a b Figure 1 . Different patterns of signal intensity of CNVs (copy-number variations; one-copy duplication and one-copy deletion) for oligonucleotide-comparative genomic hybridization (CGH) and short nucleotide polymorphism (SNP) genotyping arrays. These arrays have been used to detect CNVs; however, oligonucleotide-CGH generated only one type of signal intensity data that is, log ratio compared with the SNP genotyping array where both log ratio and B allele frequency (BAF) were generated. (a) In array CGH, the signal intensity ratio between a test sample and a reference sample (one sample or a pool of samples can be used as a reference) is normalized and converted to a log2 ratio, which acts as a proxy for copy number. An increased log2 ratio represents a gain in copy number in the test compared with the reference; conversely, a decrease indicates a loss in copy number. SNP array generates a similar metric by comparing the signal intensity of the sample being analyzed to a collection of reference signal intensities. (b) By contrast, BAF was generated only by SNP array. BAF is the proportion of the total allele signal (A þ B) explained by a single allele (A) and can be interpreted as follows: a BAF of 0 represents the genotype (A/A or A/À), whereas 0.5 represents (A/B) and 1 represents (B/B or B/À). Different BAF values occur for one-copy duplication and one-copy deletion compared with normal haploid copy.
WES refers to the sequencing of the entire set of exons (B200 000 exons) in the genome. It requires several sequenceenrichment steps followed by massively parallel sequencing. The development of commercial whole human exome enrichment kits has been largely responsible for making this approach feasible in practical terms. During the enrichment steps, the genomic regions of interest (that is, all exons) are captured through hybrid selection of DNA fragments using oligonucleotide probes, whereas the unwanted DNA sequences (that is, the non-coding regions) are removed before sequencing, leading to a significant reduction in the proportion of the genome that needs to be sequenced. The difference between on-solid and in-solution capture methods is that the oligonucleotide probes are tethered on microarray or are suspended in-solution, respectively. The performance of different commercial exome-enrichment methodologies has been evaluated, with pros and cons associated with each of the methods. 44--47 Figure 2 illustrates a general workflow of WES from genomic DNA extraction to biological interpretation and the identification of the causal mutation. However, in the context of de novo mutations, intersecting with the exome data from parents is needed to distinguish them from inherited variants.
An inherent limitation of NGS technologies (particularly Illumina GA/HiSeq and ABI SOLiD) is, however, the short length of the sequence reads, which therefore needs to be computationally aligned to the reference genome using conventional alignment tools. The alignment steps are then followed by variant calling and filtering to remove false positives, and variant annotation to obtain information such as genomic position. Although most of the studies have adopted the alignment or mapping approach, it is widely anticipated that with rapid developments in sequencing technologies designed to produce longer sequence read lengths 48 and more powerful analytical tools, 14 de novo genome assembly will become even easier. 13 In de novo genome assembly, the sequence reads are assembled into contigs by bioinformatic means without mapping against a reference genome sequence; as such, this process of assembly has the potential to identify new or previously unknown sequences (and hence the variants within these sequences). It follows that de novo genome assembly should make possible the more thorough and potentially comprehensive detection of the various types of genetic variant, including those that have occurred de novo.
DE NOVO MUTATION RATES
Recent studies have estimated the per-generation mutation rate in humans to be between 7.6 Â 10 À9 and 2.2 Â 10 À8 (see refs. 11, 49) . This equates to an average of 50--100 de novo mutations in a newborn genome, which corresponds to B0.86 de novo aminoacid-altering mutations. The genome-wide CNV mutation rate has also been estimated using SNP microarrays; at a resolution of o30 kb, Exomes of 10 case-parent trios.
All cases had moderate-to-severe mental retardation and a negative family history.
Array-based genomic profiling did not reveal de novo or other CNVs. Exomes from 14 trios, with each trio consisting of an individual with schizophrenia and his or her parents.
None of the selected probands had a first-or second-degree family history of psychotic disorders. Examined genomic DNA from every selected trio using a CNV-targeted array to exclude potentially causative structural genetic variations.
An average of B56 million reads were available for each individual, of which B50% aligned to the targeted regions.
An average of B72% of targeted regions covered with a read depth 420 Â .
Autism spectrum disorders (ASDs) O'Roak et al.
17
Roche SeqCap EZ Exome probes v.1.0 Illumina Genome Analyzer IIx 20 trios with an idiopathic ASD, each consistent with a sporadic ASD.
Each family was initially screened by arraycomparative genomic hybridization.
Identified no large (4250 kb) de novo CNVs but did identify a maternally inherited deletion (B350 kb) at 15q11.2 in one family (this deletion has been associated with an increased risk of epilepsy and schizophrenia but has not been considered causal for autism).
Obtained sufficient coverage to call variants for B90% of the primary target (26.4 Mb).
Genotype concordance with SNP microarray data was 99.7% and on average.
Abbreviations: ASDs, Autism spectrum disorders; CNVs, copy-number variants.
De novo mutations in inherited disease CS Ku et al
Itsara et al. 50 observed nine de novo CNVs from 772 transmissions, corresponding to a mutation rate of 1.2 Â 10 À2 CNVs per genome per transmission. However, as yet, a direct comparison of male with female germline mutation rates with complete genome sequences has not been performed. Thus, the gender-specific mutation rates still remain to be formally ascertained. Complete genomes from two parent-offspring trios (from the HapMap CEU (Utah residents with Northern and Western European ancestry) and YRI (Yoruba people in Ibadan, Nigeria) populations) were sequenced to 422-fold mapped depth during the pilot phase of the 1000 Genomes Project; 51 a total of 49 and 35 germline de novo mutations were identified in two parent-offspring (CEU and YRI) trios, respectively. 1 In cellula and somatic mutations may have adversely affected published estimates of de novo mutation rates. To take these artifacts into consideration, Conrad et al 1 performed validation of all putative de novo mutations detected to unambiguously distinguish germline de novo mutations from somatic or in cellula mutations. Thus, the de novo mutations were classified into five categories that is, (a) germline de novo mutations, (b) non-germline (somatic or arising in cellula) de novo mutations, (c) inherited variant, (d) false positive and (e) inconclusive. In addition to the germline de novo mutations, through validation and classification, the study also detected 952 and 643 non-germline de novo mutations in the CEU and YRI trios, respectively. The observed ratio of non-germline versus germline de novo mutations was substantially greater than the 1:1 ratio reported previously. This difference could be because of the age of the cell lines (number of passages), the mutagenicity of the cell culture conditions and/or the clonality of the cell lines. However, to ensure that mutations are truly germline and occurred in the parents, a three-generation study is required to demonstrate that the de novo mutations in the second generation have been transmitted to the third generation. Alternatively, DNA from another tissue for example, skin (assuming DNA from peripheral blood was used for the analysis of de novo mutations) in the offspring needs to be tested to discern whether the mutations that were absent in parents are germline de novo or somatically acquired. If the former, theoretically these mutations should also be observed in another constitutional tissue, otherwise they are likely to have been somatically acquired. Further, in addition to the estimation of the germline de novo mutation rate, differences in parental transmission were also observed. In one family, 92% of the de novo mutations originated from the paternal germline, whereas the equivalent figure in the other family was 36% of de novo mutations. 1 In future, an in-depth investigation of the variation in mutation rates within and between families/populations will require a larger sample size.
The estimation of the de novo mutation rate using WES could be affected by the incomplete capture of the known exons. However, the implications for the de novo mutation rate calculations will depend upon whether the incomplete capture of the exons is random or systematic (for example, exons with low/high GC content that have been reported to have lower capture efficiency, or exons with a specific sequence feature such as highly repetitive sequences). The former is unlikely to affect the estimation of the de novo mutation rate significantly. By contrast, the effects of exons with low/high GC content on the estimation of the de novo mutation rate will depend upon whether this specific group of exons has a significantly lower/higher than average de novo mutation rate as compared with the other exons. Unfortunately, there are no empirical data available to demonstrate this one way or the other. Thus, the consequences of the incomplete capture of exons on estimates of the de novo mutation rate remain speculative.
DE NOVO MUTATIONS IN NEURODEVELOPMENTAL DISOR-DERS
Rett syndrome: a classical example of a neurodevelopmental disorder affected by de novo mutations A classical example of a neurodevelopmental disorder caused by de novo mutations is Rett syndrome. It is a progressive neurodevelopmental disorder and one of the most common causes of mental retardation. The syndrome is transmitted as an X-linked dominant trait, and therefore almost exclusively affects females. Further, the syndrome is sporadic in most cases. 52 One of the first pieces of evidence showing the importance of de novo mutations Figure 2 . A general workflow of whole-exome sequencing (WES) from genomic DNA extraction to biological interpretation and the identification of the causal mutation. The workflow is divided into three phases, that is, sample preparation and sequencing (steps 1--4), primary data processing (steps 5--7) and secondary data processing (steps 8--10). The genomic DNA is used for sequencing library preparation involving several steps such as DNA fragmentation and adapter ligation (steps 1 and 2). Exome capture and enrichment is usually performed using commercial kits such as the Agilent (Agilent Technologies, Santa Clara, CA, USA), Illumina, and Nimblegen (NimbleGen Systems, Madison, WI, USA) human exome capture kits. WES is then performed using high-throughput next-generation sequencing (NGS) technologies such as Illumina GA/HiSeq, Life Technologies SOLiD (Life Technologies), and Roche 454 Genome Sequencer. These steps are performed according to the manufacturer's recommended protocols. An average coverage of B30-fold is deemed sufficient for the accurate calling of variants (steps 3 and 4). Subsequently, the data from NGS platforms are processed to raw sequence reads (step 5). These reads are then aligned to the reference genome using conventional alignment tools. PCR duplicates, which introduce noise to variant calling, are removed (steps 6 and 7). The analytical pipeline is then followed by variant calling and filtering to remove false positives according to commonly applied quality control criteria (step 8). Finally, the variants are annotated to obtain information such as genomic position and functional effect (for example, missense and nonsense variants; step 9), before being examined to identify the causal mutations (step 10).
Biological interpretation and identification of causal mutation
Primary Data Processing
Secondary Data Processing
in Rett syndrome was the identification of a de novo-balanced translocation between chromosomes X and 3 (with the chromosome constitution 46,X,t(X;3)(p22.11;q13.31)). 53 This genetic evidence is in line with the hypothesis of an X-linked dominant mutation. The mode of inheritance of Rett syndrome as an X-linked dominant disorder was further supported by the identification of mutations in MECP2. 54 More interestingly, in 5 of 21 sporadic patients, three de novo missense mutations were found in the region encoding the highly conserved methyl-binding domain, as well as a de novo frameshift and a de novo nonsense mutation, both of which disrupted the transcription repression domain. Approximately 80% of Rett syndrome cases are sporadic and caused by mutations in the MECP2 gene. Almost all mutations in MECP2 occur de novo, suggesting that such mutations are largely responsible for the almost invariable occurrence of this highly deleterious disorder in females and presumed lethality in males. 52,54--56 Common neurodevelopmental disorders A comprehensive summary of de novo mutations in rare Mendelian forms of neurodevelopmental disorders is beyond the scope of this review. Instead, we focus on the importance of de novo mutations in common neurodevelopmental and neuropsychiatric disorders such as schizophrenia, autism and mental retardation.
It has been postulated that the occurrence of de novo mutations might explain why diseases characterized by dramatically reduced fecundity such as mental retardation and schizophrenia nevertheless remain frequent in the population. If this were indeed to be the case, the de novo mutations occurring in sporadic cases of these diseases would serve to replenish the number of highly penetrant disease mutations in every generation despite the continual negative selection. Indeed, de novo CNVs are a known cause of schizophrenia, autism and mental retardation. For example, in one of the first CNV studies to examine de novo CNVs in schizophrenia, Xu et al. 10 showed that de novo CNVs are significantly more common in sporadic cases than in controls that is, 10 versus 1.3%, respectively. A recent analysis of de novo CNVs implicated the involvement of postsynaptic signaling complexes in the pathogenesis of schizophrenia. 57 Similarly, de novo CNVs have also been found to be associated with autism and/or ASD and mental retardation. 9,58--62 For example, a recent genome-wide analysis was performed to examine rare CNVs in 1124 ASD families (each family comprising a single proband and their unaffected parents), which identified multiple rare recurrent de novo CNVs, in particular a significant association of ASD with the de novo duplication of 7q11.23. 60 The identification of de novo and inherited CNVs in neurodevelopmental disorders has been reviewed elsewhere.
63--66
De novo point mutations have also been identified in schizophrenia through the exome sequencing of affected caseparent trios. The study of Xu et al. 18 is by far the largest in this context; the exomes of 53 sporadic schizophrenia cases (with no history of the disease in a first-or second-degree relative), 22 unaffected controls and their parents were sequenced. This endeavor identified a total of 34 de novo point mutations (33 SNVs and 1 dinucleotide substitution) and 4 de novo indels in the affected trios. Further, this analysis identified an excess of nonsynonymous changes amongst the identified de novo mutations in schizophrenia cases, as well as an increased likelihood of these missense variants affecting protein structure and function when compared with the rare inherited variants identified in the same study. Thus, of the 34 de novo point mutations, 32 were missense mutations, 19 of which affected evolutionarily conserved positions and were predicted (by PolyPhen-2 analysis) to alter protein function. 18 In addition, three of the indels resulted in protein truncations and one gave rise to a single amino-acid deletion. Overall, 27 out of 53 cases of schizophrenia (B51%) were found to carry at least one de novo mutational event. It is noteworthy that de novo SNVs (four non-synonymous and three synonymous mutations) were also identified in the control subjects. 18 This suggests that identifying the pathogenic and deleterious de novo mutations from among a background of non-disease-associated SNVs is likely to be a tricky task. However, the finding of a significantly larger than expected number of de novo mutations in schizophrenia probands appears to be supported by the results of another study. 19 It could, of course, be that this excess of de novo mutations is simply a proxy indicator of increased genome-wide mutability and that only one mutation, possibly not even one within the exome screened, in each case is responsible for the disease. Tables 1 and 2 summarize the (a) experimental designs and (b) analysis pipeline and major findings, respectively, for the WES studies.
In a parallel development, de novo mutations were also found to be enriched in ASD in a WES study of 20 sporadic ASD cases and their parents; 18 de novo-coding mutations were identified, of which 11 were protein altering. 17 Potentially causative de novo mutations were identified in the FOXP1, GRIN2B, SCN1A and LAMC3 genes in four ASD probands who were among the most severely affected individuals studied. 17 Interestingly, de novo mutations in some of these genes have already been previously found in association with a variety of neurodevelopmental phenotypes. For example, in an earlier study, which sequenced the GRIN2B gene in 468 individuals with mental retardation, four de novo mutations in the gene were identified. 67 Similarly, de novo mutations in the FOXP1 gene have also been identified in individuals with intellectual disability, autism and language impairment. 7, 68 This is therefore suggestive of a pleiotropic effect for these genes in different neurodevelopmental disorders---de novo mutations in these genes could give rise to variable phenotypic expressivity or even a spectrum of neurodevelopmental phenotypes, depending upon mutation severity and probably modulated by other genetic and environmental factors. 69 De novo point mutations have also been identified in individuals with unexplained mental retardation. More specifically, Vessers et al. 12 employed the WES approach to identify de novo point mutations in children with a normal karyotype in whom arraybased genome profiling had excluded a potential contribution from de novo CNVs, a known cause of mental retardation. Thus, WES was performed on 10 children with unexplained mental retardation and their parents, leading to the identification of an average of 21 755 genetic variants per individual. One of the main challenges in WES is therefore clearly the huge number of variants found in each exome and in identifying the causal mutation responsible for the disease. As with other WES studies, a series of filtering steps were applied and, after validation by Sanger sequencing, a total of nine de novo mutations were identified. The commonly applied filters serve to exclude (a) all nongenic, intronic and synonymous variants (as these variants do not alter the amino-acid sequence of the gene concerned and are much less likely to be causally related), (b) known and likely benign variants by comparison with SNP databases and 1000 Genomes Project to exclude common variants and (c) inherited variants by comparison with the parental genomes. 12 These de novo mutations occurred in different genes, including RAB39B and SYNGAP1, which have previously been implicated in mental retardation, 70, 71 thereby lending further support to the results derived from exome sequencing. Six of these nine de novo mutations were predicted to be pathogenic on the basis of gene function, evolutionary conservation and likely mutational impact. 12 In addition to data from genome-wide CNV and WES analyses, evidence is also accumulating from studies that have employed a more targeted gene-centric approach; such studies have identified de novo CNVs and point mutations for a number of different neurodevelopmental disorders. 72, 73 However, this targeted approach is hypothesis-driven. For example, on the basis that 
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Explored the possibility that de novo mutations in cases have a greater potential to affect protein structure and function than private-inherited variants by examining the evolutionary conservation of affected nucleotides (using the phyloP score20) as well as the potential of the de novo protein-altering mutations to affect the structure or function of the resulting proteins (using the Grantham score 21) Compared the cumulative distribution of these scores between de novo and private-inherited variants in the sporadic cases cohort, and observed that the distribution of the de novo variants was clearly shifted to the right (phyloP P ¼ 0.0005 and Grantham P ¼ 0.14).
Cases
The variant filtering steps were not described in detail.
Observed a total of 34 de novo point mutations (33 SNVs and 1 dinucleotide substitution) and 4 de novo indels in the affected trios.
All identified de novo mutations were absent in a total of 1658 control chromosomes. Controls Using the same pipeline and filtering criteria, identified seven exonic de novo SNVs but no indel in 7 out of 22 control subjects.
Found 27 out of 53 cases (B51%) harboring at least one de novo mutational event.
10 of the 27 cases carried more than one de novo mutation, and the rest each carried a single mutation or indel.
In sporadic schizophrenia cases, rare de novo variants are approximately ten times more likely than inherited rare variants to harbor non-synonymous changes. Controls 7 out of 22 controls carry at least one de novo event, with one control having more than one de novo mutation.
Schizophrenia
Girard et al.
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Among the 11 missense de novo mutations identified, 7 were predicted to be deleterious when analyzed using the bioinformatic algorithms SIFT, PolyPhen, the PhyloP conservation score or the Grantham matrix. Two missense variants in CCDC137 and CHD4, respectively, were predicted to be damaging by all four prediction algorithms.
Examined any variation from the reference genome in his or her unaffected parents and in a pool of 26 control individuals (comprising the parents of the other trios) and placed every variant found to be unique to the proband on a putative de novo mutation list. This approach led to the identification of 11 de novo mutations, 10 of which were deemed to be potentially deleterious (that is, three nonsense, two splicing, one frameshift, four missense) and one synonymous substitution in eight different genes. De novo-truncating and/or -splicing mutations in SYNGAP1, STXBP1 and SHANK3 were noted in six patients and were held to be probably pathogenic. In addition, de novo missense mutations in KIF1A, GRIN1, CACNG2 and EPB41L1 were deemed to be potentially pathogenic. In earlier studies, de novo mutations in STXBP1 have already been identified in patients with severe mental retardation and nonsyndromic epilepsy 74 and early-onset epileptic encephalopathy 75 also by a means of targeted gene sequencing. Although most of the targeted sequencing studies have employed traditional PCR-Sanger sequencing, this approach has now been augmented by high-throughput multiplex-PCR and custom enrichment methods, and NGS technologies to selectively enrich for specific genes, allowing up to hundreds of genes to be sequenced efficiently.
Rare Mendelian disorders associated with neurodevelopmental defects In addition to common diseases, de novo mutations have also been found to have an important role in sporadic cases of Mendelian disorders associated with neurodevelopmental defects. A good example is provided by one of the first exome-sequencing studies performed in Kabuki syndrome with a hitherto unknown genetic etiology. 20 Kabuki syndrome is a multiple malformation disorder characterized by mild-to-moderate mental retardation in addition to a distinctive facial appearance and various congenital cardiac, skeletal and immunological anomalies. It is an extremely rare autosomal-dominant Mendelian disorder, with the majority of reported cases being sporadic. De novo mutations have been suspected to be responsible for these sporadic cases. More specifically, a total of 33 distinct mutations in the MLL2 gene were identified in 35 of 53 individuals or families, with Kabuki syndrome using exome sequencing and follow-up-targeted sequencing. In accord with the original hypothesis, the MLL2 mutation was found to have occurred de novo in all 12 cases where DNA from both parents was available. 20 The de novo nature of the mutations in MLL2 for Kabuki syndrome has been further demonstrated by follow-up studies. 76--78 Indeed, MLL2 mutations have been found in a majority of 110 families with Kabuki syndrome (74%) in an independent study and in those 25 cases where DNA was available from both parents, all mutations were confirmed to be de novo.
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In similar vein, most cases of Schinzel--Giedion syndrome occur sporadically, suggesting that heterozygous de novo mutations may be responsible for causing this disorder. This syndrome is also characterized by severe mental retardation, distinctive facial features and multiple congenital malformations. De novo causal mutations in SETBP1 were first identified in four individuals with this disorder through exome sequencing. 21 Further sequencing of SETBP1 identified de novo mutations in an additional six (of eight) cases with parental samples. All these mutations affected aminoacid residues within a highly conserved domain of SETBP1, consistent with their deleterious effect. Thus, it should be noted that the degree of nucleotide-level evolutionary conservation can be used as an indicator of the deleterious nature and potential pathogenicity of de novo mutations. Finally, de novo nonsense (protein-truncating) mutations in the ASXL1 and KAT6B genes have also been found to cause Bohring--Opitz syndrome (characterized by severe intellectual disability, distinctive facial features and multiple congenital malformations) and Say-Barber-BieseckerYoung-Simpson syndrome (a multiple anomaly syndrome which is also characterized by severe intellectual disability), respectively. 22, 79 In addition, numerous studies have now applied WES to the identification of de novo mutations in a range of rare diseases (Table 3) . 80--93 Taken together, these studies have demonstrated the power of exome sequencing in revealing causal genes for Mendelian disorders with hitherto unknown genetic etiology as well as identifying de novo point mutations when parental samples are available. More importantly, these results suggest that de novo mutations are a likely cause of sporadic conditions with reduced fecundity, such as congenital malformations, mental retardation and various psychiatric disorders.
PERSPECTIVES AND CONCLUSIONS
The development of sequence-enrichment methods and NGS technologies has made WES a very powerful and cost-effective research tool that can completely bypass the hypothesis-driven targeted approach of sequencing a limited set of candidate genes. However, the current shortcoming of WES lies in its limited ability to study CNVs, and its necessary focus on coding regions. Hence, the clinicobiological importance of de novo mutations in noncoding regions remains unclear. Eventually, WGS and especially de novo genome assembly promises to permit the comprehensive analysis of de novo mutations and other inherited variants in the human genome in collections of case-parent trios affected by various heritable diseases. As a considerable number of inherited mutations for various diseases have now been found in noncoding regions, 94 it is reasonable to suppose that this could also pertain to de novo mutations within non-coding regions. This in turn supports the likely efficacy of the strategy of eventually Determined by simulation of the expected mean GERP and Grantham distributions for ten randomly selected common or private control SNVs.
Compared the observed means of the ten de novo protein-altering ASD proband variants with the distribution of common control SNVs; they corresponded to more highly conserved (GERP, Po0.001) and disruptive amino-acid mutations (Grantham, P ¼ 0.015).
Abbreviations: ASDs, Autism spectrum disorders; dbSNP, single nucleotide polymorphism databases; SNVs, single nucleotide variants.
De novo mutations in inherited disease CS Ku et al A rare, multiple malformation disorder characterized by a distinctive facial appearance, cardiac anomalies, skeletal abnormalities, immunological defects and mild-to-moderate mental retardation.
Seven probands had newly identified nonsense or frameshift mutations in MLL2 gene. Follow-up Sanger sequencing detected MLL2 mutations in two of the three remaining individuals with Kabuki syndrome, and in 26 of 43 additional cases. In families where parental DNA was available, the mutation was confirmed to be de novo (n ¼ 12) or transmitted (n ¼ 2) in concordance with the phenotype.
Hoischen et al.
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Schinzel--Giedion syndrome (MIM# 269150)
Characterized by severe mental retardation, distinctive facial features, multiple congenital malformations (including skeletal abnormalities, genitourinary and renal malformations, and cardiac defects) and a higher-than-normal prevalence of tumors, notably neuroepithelial neoplasia.
Heterozygous de novo variants identified in SETBP1 gene in four affected individuals. The study also identified SETBP1 mutations in eight additional cases using Sanger sequencing. For six of the eight followup cases, parental DNA was available, and the mutations present in the affected individuals were again shown to have occurred de novo.
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Bohring--Opitz syndrome (MIM# 605039)
Characterized by severe intellectual disability, prominent metopic suture, exophthalmus, forehead nevus flammeus, upslanting palpebral fissures, ulnar deviation and flexion of the wrists and metacarpophalangeal joints, and severe feeding problems.
Heterozygous de novo nonsense mutations identified in ASXL1 gene in three individuals with Bohring--Opitz syndrome. Analysis of additional samples found that in total, 7 out of 13 subjects with a Bohring--Opitz phenotype had de novo ASXL1 mutations. A child with classic features of hypothyroidism (growth retardation, developmental retardation, skeletal dysplasia and severe constipation) but only borderlineabnormal thyroid hormone levels.
De novo heterozygous nonsense mutation identified in the THRA gene encoding thyroid hormone receptor alpha, generating a mutant protein that inhibits wildtype receptor action in a dominant-negative manner.
Simpson et al.
GPS (MIM# 606170)
A rare disorder in which patellar aplasia or hypoplasia is associated with external genital anomalies and severe intellectual disability.
De novo mutations of KAT6B gene identified in five individuals with GPS; a single nonsense variant and three frameshift indels, including a 4-bp deletion observed in two cases. All identified mutations are located within the terminal exon of the gene and are predicted to generate a truncated protein product lacking evolutionarily conserved domains.
Campeau et al.
A rare skeletal dysplasia combining hypoplastic or absent patellae, genital anomalies, craniofacial defects, and intellectual disability among other features.
De novo heterozygous-truncating mutations identified in KAT6B gene in three subjects; Sanger sequencing of KAT6B was used to identify similar mutations in three additional subjects. The mutant transcripts do not undergo nonsense-mediated decay in cells from subjects with GPS.
Sirmaci et al.
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KBG syndrome (MIM# 148050)
Characterized by intellectual disability associated with macrodontia of the upper central incisors as well as distinct craniofacial findings, short stature and skeletal anomalies.
Deleterious heterozygous mutations identified in ANKRD11 gene encoding ankyrin repeat domain 11. A splice-site mutation, c.7570-1G4C (p.Glu2524_Lys2525del), co-segregated with the disease in a family with three affected members, whereas in a simplex case a de novo-truncating mutation, c.2305delT (p.Ser769GlnfsX8), was detected. Sanger sequencing revealed additional de novo-truncating ANKRD11 mutations in three other simplex cases.
Gibson et al.
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Weaver syndrome (MIM# 614421)
A rare congenital anomaly syndrome consists of generalized overgrowth, advanced bone age, marked macrocephaly, hypertelorism and characteristic facial features. Intellectual disability is common.
Two different de novo mutations identified in EZH2 gene. Sanger sequencing of EZH2 in a third classically affected proband identified a third de novo mutation in this gene.
Hood et al.
FHS (MIM# 136140)
A rare condition characterized by short stature, delayed osseous maturation, expressive-language deficits and a distinctive facial appearance.
Heterozygous truncating mutations identified in SRCAP gene in five unrelated individuals with sporadic FHS. Sanger sequencing identified mutations in SRCAP in eight additional affected persons. Mutations were found to be de novo in all six instances in which parental DNA was available.
adopting WGS to ascertain the full impact of de novo mutations in human genetic disease and to study the molecular characteristics of such lesions.
Collections of a large number of such trios would be important in this context. Although genome-wide SNP arrays were applied, Stefansson et al. 95 analyzed 9878 parent-to-offspring transmissions to identify de novo CNVs. The identified de novo CNVs were then tested for association in 1433 schizophrenia cases and 33 250 controls. The case-parent trio study design is gaining in popularity; in addition to being able to detect de novo events, this study design should also be capable of determining the parent of origin of the mutations, for example, the paternal versus the maternal A developmental disorder characterized by reduced growth, generalized muscular hypertrophy, facial dysmorphism, deafness, cognitive deficits, joint stiffness and skeletal anomalies.
Heterozygous mutations identified in the SMAD4 gene, which encodes for a transducer mediating transforming growth factor b and bone morphogenetic protein-signaling branches. Two recurrent de novo SMAD4 mutations were identified in eight unrelated subjects.
Abbreviations: ADCA-DN, autosomal-dominant cerebellar ataxia, deafness and narcolepsy; FHS, Floating-Harbor syndrome; GPS, Genitopatellar syndrome; HDLS, hereditary diffuse leukoencephalopathy with spheroids; MFDM, mandibulofacial dysostosis with microcephaly; PPK, palmoplantar keratoderma; SBBYSS, Say-Barber-Biesecker-Young-Simpson syndrome. We have included all recent studies applying the whole-exome sequencing approach that identified de novo mutations in rare disorders. However, the list is by no means complete. This table briefly summarizes the studies, which have applied whole-exome sequencing to identify de novo mutations in rare disorders together with their major findings. However, readers are encouraged to refer to the full papers for more detailed information.
haplotype. The importance of studying parent of origin effects has already been demonstrated in genome-wide association studies of inherited variants for complex diseases. 96 The de novo point mutations and CNVs discovered to date in neurodevelopmental disorders are likely to represent only the tip of the iceberg. Although WES also allows the detection of larger CNVs using depth-of-coverage from mapped short sequence reads, 97 this approach suffers from the same inherent limitation that only coding regions are currently being interrogated. The potential contribution of de novo mutations residing in other regions of the genome remains to be explored. A further limitation of WES is that coverage of the entire exome is not complete using the existing commercial enrichment kits. Although whole-genome SNP genotyping arrays allow a relatively unbiased genome-wide survey of CNVs across the entire genome, they are a rather blunt tool in terms of their sensitivity with respect to the detection of CNVs as compared with NGS-based approaches. 98, 99 However, studies performed to date have generated sufficient data to justify the application of WGS to assess the contribution of various types of de novo mutation, particularly in the context of neurodevelopmental and neuropsychiatric diseases. Taken together, these studies support the emerging general postulate that the genetic basis of sporadic cases of neurodevelopmental disorders is more likely to involve de novo mutations than inherited variants. On the basis that neurodevelopmental disorders share some genetic (that is, overlap of genetic loci) and pathological (overlap of phenotypic manifestations) basis, 61, 100, 101 newly identified de novo mutations in one disorder should also be sought in other related conditions. More specifically, pleiotropic effects have recently been demonstrated, by means of WES, for other neurological diseases such as VCP mutations in amyotrophic lateral sclerosis 102 and NOTCH3 mutations in Alzheimer disease, 103 further emphasizing that these effects may have a more significant role in neurological disease than previously appreciated. Indeed, the entire gene in which the de novo mutation is found should be screened (instead of just the single mutation) in other related conditions, in order to allow for the possibility of allelic heterogeneity, a situation in which different de novo mutations in the same gene are responsible for different diseases. In parallel to the emergence of sequencing technologies capable of generating longer sequence reads and the development of ever more powerful bioinformatics tools, the study of de novo mutations in the human genome would be further facilitated by de novo genome assembly. This would allow the contribution of de novo mutations to genetic disease to be fully assessed genome wide. Although the importance of de novo mutations to the etiology of common neurodevelopmental disorders has been relatively well established, their significance in the context of other types of inherited disease still remains to be examined. For example, sporadic cases of nonsyndromic tetralogy of Fallot (the most common severe congenital heart malformation) also commonly result from de novo CNVs. 104 The high-throughput sequencing (both WES and WGS) of case-parent trios as part of a strategy to search for disease-causing mutations should be advocated as this study design possesses distinct advantages, which cannot be substituted by the study of samples from unrelated individuals. In the light of the expected increase in number of reported de novo mutations and their associations with various human diseases, a curated database to catalog all such mutations is seen as an invaluable research tool for the future.
Finally, the diagnostic application of exome sequencing has been increasingly demonstrated in identifying inherited causal mutations for Mendelian disorders. 105--107 Montenegro et al.
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showed the feasibility and power of WES as a diagnostic tool in two affected individuals from a family with Charcot--Marie--Tooth disease (an inherited peripheral neuropathy characterized by extensive locus heterogeneity involving mutations in at least 35 genes). The analysis identified a nonsynonymous mutation in GJB1, a variant that had been reported previously as being pathogenic in X-linked Charcot--Marie--Tooth families. Hence, the prospect of this application is also to be anticipated in the context of de novo mutations in sporadic cases of neurodevelopmental diseases or Mendelian disorders if parental samples are available. Indeed, just as the use of microarrays to detect CNVs has revolutionized the clinical diagnostic approach to individuals with disorders such as intellectual disability, 37,108--110 WES and WGS are increasingly acquiring a dual role as both a discovery and a diagnostic tool in neurodevelopmental and neuropsychiatric disease. It follows that microarrays could eventually be supplanted by WGS as a single diagnostic test for various genetic variants. A further advantage of WGS lies in its ability to detect CNVs and structural rearrangements in addition to point mutations and small indels. In contrast to WES, WGS has clear advantages in detecting CNVs and structural rearrangements based on both the detection methodology that is, paired-end mapping and/or depth-of-coverage. Further, not only do the reads generated by WGS cover the entire genome but WGS also avoids the biases introduced by exome enrichment in WES (for the depth-ofcoverage method) in identifying/predicting CNVs. 98, 99 Note added in proof While this review paper was being typeset, three studies appeared which described the identification of de novo mutations in autism spectrum disorders by means of the WES approach.
111--113 These findings provide further support for the importance of de novo mutations in the etiology of these complex disorders. For example, in their large-scale study of 928 individuals, including 200 phenotypically discordant sib-pairs, Sanders et al. 112 found that the highly disruptive (nonsense and splice-site) de novo mutations in brain-expressed genes were not only associated with autism spectrum disorders but also carried large effects. Further, the occurrence of multiple independent de novo single nucleotide variants in the same gene among unrelated probands was found to be a reliable identifier of risk alleles, thereby providing a new approach to gene discovery in autism spectrum disorders.
